← All trials
NCT02205008
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2012
- Primary completion
- Dec 1, 2015
- Completion date
- Nov 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 230
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Kyungpook UniversityLead sponsor
- National Cancer Center, KoreaCollaborator
- Korea Cancer Center HospitalCollaborator
- Hanyang UniversityCollaborator
- Chonnam National UniversityCollaborator
- Yonsei UniversityCollaborator
- Daegu Catholic UniversityCollaborator
- Dong-A UniversityCollaborator
- Yeungnam UniversityCollaborator
- Keimyung UniversityCollaborator
- Kyungpook UniversityOverall official - principal investigator
- Kyungpook UniversityReponsible party - principal investigator
- Chung-Ang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.